Home › PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients
 

Keywords :   


PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients

2014-05-21 18:54:23| Logistics - Topix.net

The EVOLVE trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers and the MoA trial is a phase I "window of opportunity" trial evaluating intravenous and intra-tumoural administration of enadenotucirev to patients with colon cancer.

Tags: results study release cancer

Category:Transportation and Logistics

Latest from this category

All news
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
Transportation and Logistics »
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »